Insulin suspension isophane/insulin biosimilar - Julphar

Drug Profile

Insulin suspension isophane/insulin biosimilar - Julphar

Alternative Names: Biosimilar human normal insulin/protaminated insulin suspension - Julphar; Human biphasic insulin - Julphar; Insulin human 30/70 - Julphar; Julphar Insulin 30/70; Jusline 30/70; Recombinant human insulin/protamine insulin mixture - Julphar

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Julphar Gulf Pharmaceutical Industries
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Interim efficacy and adverse events data from a phase I trial in Diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 01 Jun 2016 Julphar completes a phase I trial for Diabetes mellitus in Germany (SC) (NCT02631928)
  • 01 Feb 2016 Phase-I clinical trials in Diabetes mellitus (In volunteers) in Germany (SC) (NCT02631928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top